Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

PaperCitations, authors & open-access status

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 627 citations, 2014 year and green oa status.

627
Citations
2014
Year
green
OA Status

Related on ScholarIQ

Hiroto Miwa
Author
Journal of Clinical Oncology
Journal
Gastric Cancer Management and Outcomes
Topic
Gastric Cancer Management and Outcomes
Topic
HER2/EGFR in Cancer Research
Topic
Advanced Breast Cancer Therapies
Topic
470M+ articles · free account